ABRAXAS1

Across TCGA pan-cancer cohorts, ABRAXAS1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ABRAXAS1 data layer compared with 25 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ABRAXAS1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ABRAXAS1 expression acts as an unfavorable survival marker, although some lineages such as LUAD and CCRCC show a favorable association.

PDAC, HNSC, and LUAD are the cancer types where ABRAXAS1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	II,III,IV	0.693	0.842	.004	40	view →
HNSC	DFS	Tertile	All	0.713	0.885	.005	34	view →
LUAD	OS	Quartile	II,III,IV	0.921	0.469	.014	13	view →
CCRCC	DFS	Median	II,III,IV	0.953	0.790	.024	12	view →
LSCC	DFS	Quartile	All	0.868	0.990	.022	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ABRAXAS1–PDAC (DFS)

Open the PDAC breakdown →